Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serologic testing in inflammatory bowel disease: its value in indeterminate colitis.

K A Papadakis1, S R Targan

  • 1*Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, D-4062, Los Angeles, CA 90048, USA.

Current Gastroenterology Reports
|September 12, 2000
PubMed
Summary

Serologic testing, including antineutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA), aids in classifying inflammatory bowel diseases. These markers help identify immune triggers and guide treatment for Crohn's disease and ulcerative colitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.

Nature communications·2016
Same author

Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor.

International journal of obesity (2005)·2016
Same author

A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.

Alimentary pharmacology & therapeutics·2015
Same author

Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis.

Oncogene·2015
Same author

Long-term outcomes of thalidomide in refractory Crohn's disease.

Alimentary pharmacology & therapeutics·2014
Same author

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.

Mucosal immunology·2014

Area of Science:

  • Immunology
  • Gastroenterology
  • Clinical Diagnostics

Background:

  • Inflammatory bowel disease (IBD) classification remains challenging.
  • Heterogeneity in IBD suggests distinct immunopathogenic mechanisms.
  • Need for objective markers to guide diagnosis and treatment.

Purpose of the Study:

  • To explore the utility of serologic markers in classifying IBD.
  • To identify antigenic triggers and immune dysregulation in IBD.
  • To assess the role of serologic markers in indeterminate colitis.

Main Methods:

  • Review of studies utilizing serologic markers like ANCA and ASCA.
  • Analysis of marker associations with IBD phenotypes.
  • Investigation of marker utility in differentiating IBD subtypes.

Related Experiment Videos

Main Results:

  • ANCA and ASCA are established markers for classifying Crohn's disease and ulcerative colitis.
  • These markers correlate with specific disease phenotypes and treatment responses.
  • Emerging data suggests potential for these markers in indeterminate colitis.

Conclusions:

  • Serologic testing offers a valuable tool for homogeneous IBD subgrouping.
  • Markers like ANCA and ASCA can elucidate immune dysregulation in IBD.
  • Further research in indeterminate colitis may refine prognosis and treatment strategies.